Quoin Pharmaceuticals Ltd
Change company Symbol lookup
Select an option...
QNRX Quoin Pharmaceuticals Ltd
INDP Indaptus Therapeutics Inc
RNAZ Transcode Therapeutics Inc
NEOV NeoVolta Inc
SYBX Synlogic Inc
FIISO Financial Institutions Inc
KA Kineta Inc
TCS Container Store Group Inc
MLGO MicroAlgo Inc
INDI indie Semiconductor Inc
Go

Health Care : Biotechnology |
Based in Israel
Company profile

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$4.70
Day's Change
-0.30 (-6.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.19
Day's Low
4.70
Volume
(Heavy Day)
Volume:
10,279

10-day average volume:
7,575
10,279

Ocugen Inc. Stock Rises Wednesday, Outperforms Market

5:15 pm ET April 26, 2023 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Ocugen Inc. (OCGN) rallied 1.39% to $0.72 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.38% to 4,055.99 and Dow Jones Industrial Average falling 0.68% to 33,301.87.

The stock's rise snapped a five-day losing streak.

Ocugen Inc. closed $2.39 short of its 52-week high ($3.11), which the company achieved on July 8th.

Trading volume (9.6 M) eclipsed its 50-day average volume of 6.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled April 26, 2023.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

	

(END) Dow Jones Newswires

April 26, 2023 17:15 ET (21:15 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.